Sunday, November 30 | 9:40 a.m.-9:50 a.m. | S1-SSGU01-5 | Room E353B
In this session, attendees will learn the benefits of using microultrasonography for detecting prostate cancer.
In his presentation, Sangeet Ghai, MD, from University Medical Imaging Toronto in Ontario, Canada, will discuss his team’s findings showing that microultrasound-guided biopsy is noninferior to MRI-guided biopsy for diagnosing prostate cancer.
The study included 802 men from 20 health centers in eight countries who had not previously undergone biopsy. The team assigned participants in a 1:2:3 ratio to receive one of the following exams: microultrasonography-guided biopsy, microultrasonography/MRI fusion-guided biopsy (where microultrasonography biopsies were performed prior to unblinding the MRI), or MRI/conventional ultrasound fusion-guided biopsy.
Of the total participants, 678 underwent biopsy. They also had an average prostate-specific antigen level of 6.9 ng/mL.
Microultrasound alone found 47.1% of prostate cancers categorized as Gleason Grade Group 2 or higher compared with 42.6% in the fusion-guided biopsy group and 46.9% in the microultrasonography/MRI group. With this finding, microultrasound alone achieved noninferiority compared with fusion-guided biopsy (p < 0.001).
Additionally, combined biopsy with microultrasonography/MRI also achieved noninferiority compared with software-assisted MRI fusion biopsy using conventional ultrasonography devices (p < 0.001).
Finally, the team reported statistically insignificant differences among the groups when it came to the rate of Gleason grade group 2 or higher cancers diagnosed. This included 38% in the microultrasonography group, 34.1% in the fusion-guided group, and 40.3% in the microultrasonography/MRI group.
Attend this session to learn more about ultrasound’s utility in this area.
